Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis

CONCLUSIONS: Treatment of patients with PSC-IBD with biologics (vedolizumab, infliximab, and adalimumab) was not associated with improvement of biochemical markers of cholestasis. Biologics are effective in treating the colitis associated with PSC. Vedolizumab was associated with worsening liver enzymes in contrast to other biologics, a finding that warrants further study.PMID:38206197 | PMC:PMC10786591 | DOI:10.1097/HC9.0000000000000347

Source: Methods of Information in Medicine - January 11, 2024 Category: Information Technology Authors: Ayesha Shah Michael P Jones Gavin Callaghan Thomas Fairlie Xiaomin Ma Emma L Culver Katherine Stuart Peter De Cruz James O'Beirne James H Tabibian Axel Dignass Ali Canbay Gregory J Gores Gerald J Holtmann Source Type: research